Starpharma Holdings (ASX:SPL) Accounts Payable: A$2.67 Mil (As of Dec. 2025)


ASX:SPL Starpharma Holdings Ltd ASX:SPL
53 GF Score
Price A$0.74
GF Value A$0.44
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Starpharma Holdings Accounts Payable?

Starpharma Holdings ASX:SPL +3.52% 53 Accounts Payable is A$2.67 Mil as of Dec. 2025. GuruFocus rates ASX:SPL with a GF Score™ of 53/100 and a GF Value™ of A$0.44 (Significantly Overvalued). The stock has 3 warning signs investors should review.

Starpharma Holdings's Accounts Payable for the quarter that ended in Dec. 2025 was A$2.67 Mil.

Starpharma Holdings's quarterly Accounts Payable declined from Dec. 2024 (A$2.66 Mil) to Jun. 2025 (A$2.05 Mil) but then increased from Jun. 2025 (A$2.05 Mil) to Dec. 2025 (A$2.67 Mil).

Starpharma Holdings's annual Accounts Payable declined from Jun. 2023 (A$6.62 Mil) to Jun. 2024 (A$2.73 Mil) and declined from Jun. 2024 (A$2.73 Mil) to Jun. 2025 (A$2.05 Mil).

Starpharma Holdings Accounts Payable Related Terms

Starpharma Holdings Accounts Payable Historical Data

* Premium members only.

The historical data trend for Starpharma Holdings's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Starpharma Holdings Accounts Payable Chart

Starpharma Holdings Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Accounts Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.71 6.76 6.62 2.73 2.05

Starpharma Holdings Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.99 2.73 2.66 2.05 2.67
ASX:SPL
53GF Score
Starpharma Holdings Ltd ASX:SPL
Accounts Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Starpharma Holdings Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of A$2.67 Mil mean?
Starpharma Holdings (ASX:SPL) has a Accounts Payable of A$2.67 Mil as of Dec. 2025. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Starpharma Holdings and its competitors.
Is Starpharma Holdings' Accounts Payable too high?
Starpharma Holdings' current Accounts Payable is A$2.67 Mil. Overall, Starpharma Holdings has a GF Score™ of 53/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Starpharma Holdings' Accounts Payable compare to VRTX and REGN?
Starpharma Holdings' Accounts Payable of A$2.67 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Biotechnology company?
A good Accounts Payable depends on the Biotechnology industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Starpharma Holdings and its competitors. Starpharma Holdings's current Accounts Payable is A$2.67 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Starpharma Holdings stock overvalued right now?
Based on GuruFocus' analysis, Starpharma Holdings (ASX:SPL) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.44, compared to a current price of A$0.74 — trading 67% above its estimated fair value. The current Accounts Payable is A$2.67 Mil. Starpharma Holdings' overall GF Score™ is 53/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For Starpharma Holdings (ASX:SPL), the current Accounts Payable is A$2.67 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Starpharma Holdings (ASX:SPL) Overvalued in 2026?

Based on GuruFocus' analysis, Starpharma Holdings stock appears to be overvalued. The current stock price of A$0.74 is trading 67% above its estimated GF Value™ of A$0.44. GuruFocus considers Starpharma Holdings to be Significantly Overvalued.

Key valuation signals for ASX:SPL:

  • Accounts Payable: A$2.67 Mil
  • GF Value™: A$0.44 vs. price of A$0.74 (67% above fair value)
  • GF Score™: 53/100 with 3 warning signs

No single metric tells the full story. See the ASX:SPL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Starpharma Holdings Business Description

Address 4-6 Southampton Crescent, Abbotsford, Melbourne, VIC, AUS, 3067
Starpharma Holdings Ltd is an Australia-based company engaged in the research, development, and commercialization of dendrimer products for pharmaceutical, life science, and other applications. It focuses on the development of VivaGel for the management and prevention of bacterial vaginosis and as a condom coating, and VIRALEZE, an antiviral nasal spray.
53GF Score

Get the complete analysis for ASX:SPL

Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.74
Price
A$0.44
GF Value